Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Adi J. Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Alexa Del Corpo, Michaël Harnois, MSc, Michel-Olivier Gratton, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Luigina Mollica, MD PhD, Pierre Laneuville, MD FRCPC, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2016) 128 (22): 3072.

https://doi.org/10.1182/blood.V128.22.3072.3072

Published: 2016

Journal Articles

Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements

Blood (2016) 128 (22): 3192.

https://doi.org/10.1182/blood.V128.22.3192.3192

Published: 2016

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Adi J Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Michel-Olivier Gratton, MSc, Michaël Harnois, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Luigina Mollica, MD FRCPC, PhD, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2015) 126 (23): 2778.

https://doi.org/10.1182/blood.V126.23.2778.2778

Published: 2015

Journal Articles

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Robert Delage, MD, MSc, FRCP, A. Robert Turner, MD, FRCPC, Brian Leber, MD, Wanda S. Hasegawa, MD, Denis-Claude Roy, MD, Mary Lynn Savoie, MD, Heather A Leitch, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Donna L. Forrest, MD, Sindu Kanjeekal, MD, Sehdev Sandeep, MD, Pierre Laneuville, MD, Sarit Assouline, MD, Kuljit Grewal, MD, Michael J. Kovacs, MD, FRCPC, Wendy Lam, MD, Annie Woo, M.Sc., Pierre Beauparlant, Ph.D., Jeffrey H. Lipton, MD, PhD

Blood (2011) 118 (21): 4437.

https://doi.org/10.1182/blood.V118.21.4437.4437

Published: 2011

Journal Articles

Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

Jean-Francois Larouche, MD, Marc Bergeron, MD, Grace Hampson, Tim Illidge, Robert Delage, MD, MSc, FRCP

Blood (2011) 118 (21): 1644.

https://doi.org/10.1182/blood.V118.21.1644.1644

Published: 2011

Journal Articles

CD19+,CD27+, IgM+ B Cells of Patients with Persistent Polyclonal B Cell (PPBL) Proliferate in a Low Intensity CD40-CD154 Interaction and Show Evidence of Immunoglobulin Isotype Switching

Robert Delage, MD, MSc, FRCP, Emmanuelle Dugas-Bourdages, MD, Annie Roy, BSc, Sonia Neron, PhD, Andre Darveau, PhD

Blood (2008) 112 (11): 4920.

https://doi.org/10.1182/blood.V112.11.4920.4920

Published: 2008

NARROW

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

CD19+,CD27+, IgM+ B Cells of Patients with Persistent Polyclonal B Cell (PPBL) Proliferate in a Low Intensity CD40-CD154 Interaction and Show Evidence of Immunoglobulin Isotype Switching

Email alerts

ASH Publications

American Society of Hematology

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

CD19+,CD27+, IgM+ B Cells of Patients with Persistent Polyclonal B Cell (PPBL) Proliferate in a Low Intensity CD40-CD154 Interaction and Show Evidence of Immunoglobulin Isotype Switching

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only